HER2-mutant non-small cell lung cancer
GPTKB entity
Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
non-small cell lung cancer subtype
|
| gptkbp:associatedWith |
female gender
adenocarcinoma histology never-smokers |
| gptkbp:clinicalTrialPhase |
DESTINY-Lung01
SUMMIT trial |
| gptkbp:diagnosedBy |
PCR
next-generation sequencing |
| gptkbp:firstDescribed |
2004
|
| gptkbp:hasAlterationType |
mutant
|
| gptkbp:hasBiomarker |
HER2 protein overexpression
HER2 gene mutation |
| gptkbp:hasIncidenceRate |
1-3% of non-small cell lung cancer cases
|
| gptkbp:hasTargetedTherapy |
HER2 inhibitor
|
| https://www.w3.org/2000/01/rdf-schema#label |
HER2-mutant non-small cell lung cancer
|
| gptkbp:isNotResponsiveTo |
EGFR inhibitors
ALK inhibitors immunotherapy (limited efficacy) |
| gptkbp:mutationAssociatedWith |
HER2
HER2 amplification HER2 exon 20 insertion HER2 point mutation |
| gptkbp:prognosis |
generally poor
|
| gptkbp:treatment |
gptkb:afatinib
gptkb:neratinib gptkb:trastuzumab_deruxtecan chemotherapy poziotinib |
| gptkbp:bfsParent |
gptkb:Trastuzumab_deruxtecan
|
| gptkbp:bfsLayer |
7
|